-
Kenya-US rare earths deal challenged in court over secrecy
-
Sinner, Djokovic set to start Wimbledon title charge
-
Santner strikes as New Zealand eye England series win
-
Pakistan launches deadliest attack on Afghanistan in months
-
Broos may change decision to quit as South Africa coach
-
Strauss 'dumbfounded' by timing of Stokes's England exit
-
French swim star Marchand suffers injury scare before Europeans
-
Monza turn to Juric for return to Serie A
-
France skipper Dupont to miss Nations Championship
-
Stocks mixed, oil edges up after US-Iran clashes
-
Springbok milestones loom for Willemse and Kolbe against England
-
Catholic traditionalists risk schism in Church
-
Tennis players end Wimbledon prize-money protest
-
Europe's deadly heatwave scorches eastern flank, takes aim at Ukraine
-
Pogacar rides with Del Toro and Yates in quest for fifth Tour de France
-
PSG in talks with Leipzig to buy Ivory Coast star Diomande
-
Australia to host Brazil double-header after World Cup
-
Venezuela search teams scramble as hope fades of finding quake survivors
-
Stocks rise and oil edges up as US, Iran call end to latest attacks
-
Bondi Beach attack survivor tells of 'trauma' of online AI images
-
South Korea to invest nearly $1.2 tn in chips, AI data centres
-
Pakistan strikes on eastern Afghanistan kill dozens
-
Russia rallies support for army with 'patriotic' tourist routes
-
Cape Verde, Africa's outlier in LGBTQ tolerance
-
Brazil, Germany eye World Cup last 16 as Netherlands face Morocco
-
South Korea demands change after dismal World Cup exit
-
Washington says US, Iran pausing strikes, talks to proceed
-
Stocks mixed and oil rises as US, Iran call end to latest attacks
-
EU, China trade tensions loom over minister visit
-
For sale on Facebook: monkeys, rhino horn and dead pangolins
-
Israelis, Palestinians torn over sacred shrine in city of Hebron
-
In Sudan's Kordofan, a key city reels as paramilitary offensive looms
-
Scheffler to face Hovland in Monday playoff for PGA Travelers title
-
Ryu Hae-ran wins Women's PGA Championship
-
'Burnt out' Stokes leaves England facing tricky questions
-
Germany must win to defy World Cup doubters, says Nagelsmann
-
Critical rescue window closing in Venezuela as quake death toll nears 1,500
-
NuRAN Wireless Is Now SEC-Registered - 40-F Declared Effective, Nasdaq Listing One Step Closer
-
Lara Exploration Announces 14,000 Metre Validation Drilling Program Underway at the Planalto Project
-
Genflow Biosciences PLC Announces Result of AGM
-
Noram Lithium Engages Triforce Media Inc. to Support Corporate Communications Strategy
-
Eco Minerals Announces Confidential Submission of a Draft Registration Statement for a Proposed Initial Public Offering
-
Ur-Energy Receives Final WDEQ Authorization to Transport Uranium-Loaded Resin from Shirley Basin to Lost Creek
-
NOVARION Systems showcases NOVARA
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 29
-
How to Start a Functional Beverage Brand: Free FMCG Webinar
-
HM Exploration Discovers New Blind Massive Sulphide Lens at Lewis Pilley's Project
-
Aclara Introduces Super Pure Rare Earth Carbonate ("SPREC")
-
Pivotree Inc. Announces Results from Its Annual and Special Meeting of Shareholders
-
Who is the Best Facial Plastic Surgeon in Seattle?
New US strategy to make monkeypox vaccine go further
US health authorities on Tuesday authorized a new procedure for injecting the monkeypox vaccine that should make it possible to inoculate more people with the same amount of the drug, at a time when doses are running short in the country.
The Food and Drug Administration also authorized giving the vaccine to people under the age of 18 who are considered to be at high risk of infection.
For those over 18, health workers will now be able to administer the vaccine differently, via an intradermal injection -- that is, between the upper layers of the skin -- and not with a deeper, subcutaneous injection.
The new method will "increase the total number of doses available for use by up to five-fold," the FDA said in a statement.
Two injections, four weeks apart, will still be necessary.
The FDA said it was drawing on data from a 2015 clinical trial that showed a similar immune response in people given a subcutaneous injection compared to those given a fifth of the dose via an intradermal shot.
At present, some 620,000 doses of the vaccine -- manufactured by Bavarian Nordic, and marketed under the name Jynneos in the United States -- have been distributed across the country.
Another 440,000 additional doses are still to be distributed, which could allow up to 2.2 million injections under the new strategy.
The government has also ordered an additional five million doses, which will start arriving from September and run through 2023, affording the potential to administer 25 million doses.
The decisions came after the FDA issued an emergency use authorization for the vaccine, a move that itself followed the declaration of a public health emergency last week.
For the authorization in minors, the FDA said it had reviewed safety data for the vaccine, as well as data for another vaccine given in children against smallpox.
"We feel very comfortable with the safety of the approach," said Peter Marks of the FDA at a press conference, noting a recent increase in the number of children who have potentially been exposed to infected people.
The United States has registered nearly 9,000 cases of monkeypox, a fifth of them in New York state. The vast majority of cases involve men who have had sex with men.
A.Clark--AT